ArimidexThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

• By Date
• Specialty Filter
• Discussions
• Top 20

Pages: 1  2  3  4  5  6  7  8  9  

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Trastuzumab plus anastrozole improves outcomes for patients with HER2/hormone receptor–copositive MBC compared with anastrozole alone, although adverse events and serious adverse events were more frequent with the combination. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Kaufman, Mackey, Clemens, Bapsy, Vaid, Wardley, Tjulandin, Jahn, Lehle, Feyereislova, Revil, Jones Tags: Chemotherapy, Breast Cancer Source Type: journals

Anastrozole: Henoch-Schonlein purpura: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 16, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Anastrozole, a selective nonsteroidal aromatase inhibitor is widely used as an adjuvant therapy for postmenopausal women with early hormone-sensitive breast cancer. There are few reports on cutaneous side effects of anastrozole. It may induce subacute cutaneous lupus erythematosus, erythema nodosum, cutaneous vasculitis, and nondescript skin eruptions. A 68-year-old woman was prescribed anastrozole after surgical removal of her breast cancer and adjuvant radiation therapy. Two months later she experienced a generalized pruritic micropapular eruption. History, clinical presentation, histology and inadvertent re-exposure...
Source: Dermatol Online J - November 13, 2009 Category: Dermatology Authors: Bremec T, Demsar J, Luzar B, Pavlović MD Tags: Dermatol Online J Source Type: journals

Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administrationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: The results indicate that, in some breast cancer patients with ordinary menopause, E2 rebounds following AI therapy. In the future, E2 monitoring should be performed for a larger number of patients being administered AI therapy.Trial registration: Our trial registration number is 19-11-1211. (Source: World Journal of Surgical Oncology)
Source: World Journal of Surgical Oncology - November 12, 2009 Category: Cancer & Oncology Authors: Taeko NagaoMisako KiraMasako TakahashiJunko HondaToshiyuki HiroseAkira TangokuHitoshi ZembutsuYusuke NakamuraMitsunori Sasa Source Type: journals

Anastrozole: Pruritic skin eruption in an elderly patient: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 11, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: The addition of a weekly tamoxifen administration did not impair anastrozole bioavailability and modulated favorably its safety profile, providing the rationale for further studies. (Clin Cancer Res 2009;15(22):7053-60). PMID: 19887477 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - November 3, 2009 Category: Cancer & Oncology Authors: Bonanni B, Serrano D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Macis D, Cazzaniga M, Luini A, Cassano E, Oldani S, Lien EA, Pelosi G, Decensi A Tags: Clin Cancer Res Source Type: journals

Arthralgia with aromatase inhibitorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: J Clin Oncol Area: News Two articles in the Journal of Clinical Oncology examine the incidence and characteristics of arthralgia associated with aromatase inhibitors in patients with breast cancer.   In the first, the authors, from an academic centre in Turkey, report a prospective case-series of patients treated with an aromatase inhibitor (for stage 1 to 3 breast cancer) who had a detailed rheumatologic assessment including autoimmune serology, musculoskeletal sonography, and electromyography (EMG). They were compared with a control group of patients not receiving hormone treatment.   In total,...
Source: NeLM - Rheumatology - October 18, 2009 Category: Rheumatology Source Type: organizations

Aromatase Inhibitor-Induced Carpal Tunnel Syndrome: Results From the ATAC Trial [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Although the use of anastrozole is associated with a greater incidence of CTS, it is rare, and most cases were of mild to moderate intensity and short duration. CTS has little impact on the overall risk-to-benefit ratio for the use of anastrozole in postmenopausal women with early breast cancer. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2009 Category: Cancer & Oncology Authors: Sestak, Sapunar, Cuzick Tags: Epidemiology, Chemoprevention studies Breast Cancer Source Type: journals

The role of Aromatase Inhibitors in the treatment of GynaecomastiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Introduction: Gynaecomastia is a benign condition of the male breast resulting from an imbalance in oestrogen/androgen ratio. Most of the circulating oestrogen is produced by the aromatisation of testosterone thus aromatase inhibitors (AIs) could be the mainstay of treatment. The aim of this study was to identify patients treated with the AI Arimidex, assess its effectiveness and identify any factors that may predict response to treatment. (Source: European Journal of Surgical Oncology)
Source: European Journal of Surgical Oncology - October 16, 2009 Category: Cancer & Oncology Authors: Asmaa Al-Allak, S. Govindarajulu, M. Shere, A. Sahu, S. Cawthorn Tags: Abstracts Source Type: journals

Anastrozole: Retinal artery occlusion: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 12, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: In older men, aromatase inhibition increases testosterone levels, decreases estradiol levels, and appears to decrease BMD. Aromatase inhibition does not improve skeletal health in aging men with low or low normal testosterone levels. PMID: 19820017 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - October 8, 2009 Category: Endocrinology Authors: Burnett-Bowie SA, McKay EA, Lee H, Leder BZ Tags: J Clin Endocrinol Metab Source Type: journals

Variation in Early Breast Cancer Systemic Adjuvant Therapy Practice among UK Oncologists with Potential Impact on Patient Benefit and the Financial Burden: National Postal Questionnaire SurveyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sir — Anonymous questionnaire survey forms were posted to 201 breast oncologists in 38 cancer networks across the UK in July 2008. Ninety-six oncologists (48%) from 35 networks (92%) responded (1–12 oncologists/network: median=2; 1–4 oncologists/hospital: median=1). For a 55-year-old fit and well woman, uses of anthracycline (no taxane) and taxane chemotherapy were 95% vs 3% for pN0, 50% vs 50% for pN1 and 9% vs 91% for pN2-3. Nine oncologists from seven networks used only anthracycline chemotherapy (no taxane) for any nodal status. Some oncologists also looked at tumour grade and oestrogen receptor status to make th...
Source: Clinical Oncology - October 5, 2009 Category: Radiology Authors: M.M.M. Moe Tags: Letters Source Type: journals

Anastrazole with or without trastuzumab for postmenopausal HER-2 positive breast cancer - results of the phase III TAnDEM studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: JCO Area: News According to research published early online in the Journal of Clinical Oncology, trastuzumab plus anastrozole improves outcomes for patients with HER2/hormone receptor-co-positive metastatic breast cancer compared with anastrozole alone.   Researchers in the TAnDEM (Trastuzumab and Anastrozole directed against ER-positive HER2-positive mammary carcinoma) study evaluated hormonal therapy with the aromatase inhibitor anastrozole in combination with trastuzumab, without chemotherapy, in postmenopausal women with HER2/hormone receptor- copositive MBC.   Postmenopausal women with HER2/ho...
Source: NeLM - Oncology - September 28, 2009 Category: Cancer & Oncology Source Type: organizations

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion First-line fulvestrant HD was at least as effective as anastrozole for CBR and ORR and was associated with significantly longer TTP. Fulvestrant HD was generally well tolerated, with a safety profile similar to that of anastrozole. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2009 Category: Cancer & Oncology Authors: Robertson, Llombart-Cussac, Rolski, Feltl, Dewar, Macpherson, Lindemann, Ellis Tags: Hormonal Therapy, Clinical Trials Breast Cancer Source Type: journals

A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study compared the effect of two sequences of aromatase inhibitor use [steroidal (exemestane) and non-steroidal (anastrozole)] on serological and pathological biomarkers when given in the neoadjuvant setting to postmenopausal women with breast cancer. Thirty women were assigned to receive exemestane 25 mg or anastrozole 1 mg each given for 8 weeks in a randomized sequence. The effect of this treatment on serum estrone sulfate and estradiol levels, as well as tumor changes in the proliferation biomarker Ki67 were evaluated at baseline, 8 weeks and 16 weeks. WHO clinical response criteria, ...
Source: Breast Cancer Research and Treatment - September 17, 2009 Category: Cancer & Oncology Tags: Breast Cancer Research and Treatment Source Type: journals

Anastrozole increases risk of carpal tunnel syndrome?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: JCO Area: News An analysis of follow up data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial in postmenopausal women with early breast cancer, has found that although the use of anastrozole is associated with a greater incidence of carpal tunnel syndrome (CTS) , it is rare, and most cases were of mild to moderate intensity and short duration.   This post-hoc analysis was based on the 100-month median follow-up data  in the two monotherapy arms (anastrozole, n = 3,092; tamoxifen, n = 3,094).   After 100 months of follow-up when all patients had completed five years of treat...
Source: NeLM - Oncology - September 15, 2009 Category: Cancer & Oncology Source Type: organizations

High-Dose Fulvestrant Helpful Against Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
For first-line endocrine therapy in advanced hormone receptor-positive breast cancer in postmenopausal women, double the approved dose of fulvestrant does at least as well as anastrozole, researchers report in the August 24th issue of the Journal of Clinical Oncology. Reuters Health Information (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 9, 2009 Category: Drugs & Pharmacology Tags: Hematology-Oncology Source Type: info

Strategies for Maximizing Growth in Puberty in Children with Short StatureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The approach to the child with growth retardation who is in puberty remains an important clinical challenge. The use of high-dose growth hormone (GH), suppression of puberty with GnRH analogs in combination with GH, and the use of selective inhibitors of the aromatase enzyme with aromatase inhibitors (also in combination with GH) are all therapeutic choices that have been studied. Aromatase blockade effectively blocks estrogen production in males with a reciprocal increase in testosterone, and a new generation of aromatase inhibitors, including anastrozole, letrozole and exemestane, is under investigation in adolescent sub...
Source: Endocrinology and Metabolism Clinics of North America - August 31, 2009 Category: Endocrinology Authors: Nelly Mauras Source Type: journals

Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: The pCR rate of the concurrent administration of chemo-endocrine therapy was not lower than those of past trials, but it remains uncertain whether this positive result was due to the administration of the aromatase inhibiter or our NAC regimen. In order to answer this, we need to make a direct comparison between the concurrent versus sequential administration of the aromatase inhibitor during NAC in a prospective study. PMID: 19728030 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Source: Breast Cancer - August 31, 2009 Category: Cancer & Oncology Authors: Watanabe N, Ootawa Y, Kodama K, Kaide A, Ootsuka N, Matsuoka J Tags: Breast Cancer Source Type: journals

Fulvestrant Shows Benefits in Advanced Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
High-dose fulvestrant, an estrogen receptor antagonist, appears to be at least as effective as the aromatase inhibitor anastrozole as a first-line endocrine therapy in postmenopausal women with advanced hormone receptor-positive breast cancer, according to research published online Aug. 24 in the Journal of Clinical Oncology. (Source: Modern Medicine)
Source: Modern Medicine - August 26, 2009 Category: Journals (General) Source Type: info

Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: TOR120 was rated excellent in acceptability, and high efficacy was observed when it was used up to third-line treatment for AI-failure cases, although this study may show some selection bias because of the retrospective study. In addition, it was also considered effective for TAM-failure cases. PMID: 19685269 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Source: Breast Cancer - August 14, 2009 Category: Cancer & Oncology Authors: Yamamoto Y, Masuda N, Ohtake T, Yamashita H, Saji S, Kimijima I, Kasahara Y, Ishikawa T, Sawaki M, Hozumi Y, Iwase H Tags: Breast Cancer Source Type: journals

Aromatase Inhibitors for Ovulation and Pregnancy in Polycystic Ovary Syndrome (July/August).Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Further trials comparing aromatase inhibitors with clomiphene citrate are necessary before aromatase inhibitors can be recommended routinely for ovulation induction in women with PCOS and infertility. However, aromatase inhibitors may be considered in a subset of this population, specifically women who are clomiphene citrate resistant or those who, after discussion of risks and benefits, are not candidates for clomiphene citrate, gonadotropins, or GnRH analogs. PMID: 19584394 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 6, 2009 Category: Drugs & Pharmacology Authors: Eckmann KR, Kockler DR Tags: Ann Pharmacother Source Type: journals

Metastasis of Lobular Breast Carcinoma to the Uterus in a Patient under Anastrozole Therapy.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: To our knowledge, this is the second case of lobular breast carcinoma metastasized to the uterus under anastrozole therapy. In women with lobular breast cancer under adjuvant anastrozole therapy, who present with vaginal bleeding, uterine metastasis of lobular carcinoma should be considered in the differential diagnosis. PMID: 19556822 [PubMed - as supplied by publisher] (Source: Onkologie)
Source: Onkologie - June 27, 2009 Category: Cancer & Oncology Authors: Ustaalioglu BB, Bilici A, Seker M, Salman T, Gumus M, Barisik NO, Salepci T, Yaylaci M Tags: Onkologie Source Type: journals

Hemicentral Retinal Artery Occlusion in a Breast Cancer Patient Using Anastrozole.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: To the best knowledge of the authors, this is the first report of hemicentral retinal artery occlusion in an anastrozole user. PMID: 19556821 [PubMed - as supplied by publisher] (Source: Onkologie)
Source: Onkologie - June 27, 2009 Category: Cancer & Oncology Authors: Karagoz B, Ayata A, Bilgi O, Uzun G, Unal M, Kandemir EG, Ozgun A, Turken O Tags: Onkologie Source Type: journals

Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Incidence of adverse events during AI therapy in this Japanese postmenopausal population appears to be lower than that of the ATAC trial. The incidence of bone fractures during AI therapy is lower in Japan, and the addition of bisphosphonates enhances bone health. We should perform a prospective trial in the future to investigate the precise risk of bone fractures in Japanese patients. PMID: 19526308 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Source: Breast Cancer - June 12, 2009 Category: Cancer & Oncology Authors: Sagara Y, Kosha S, Baba S, Dokiya F, Tamada S, Sagara Y, Matsuyama Y, Ohi Y, Ando M, Rai Y, Sagara Y, Douchi T Tags: Breast Cancer Source Type: journals

Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Aromatase inhibitors have been shown to be superior to Tamoxifen in several settings. It is unclear whether this superiority extends to their use as primary endocrine therapy in elderly patients with early operable primary breast cancer. Biological characteristics of the tumours may aid in selecting the most suitable agent.Primary endocrine therapy with Anastrozole in 64 women >70 years with oestrogen receptor α-positive (ERα+) breast cancer was compared to that in 84 treated with Tamoxifen during the same period. Biomarkers were assessed by immunohistochemistry on diagnostic core biopsies.There was no signific...
Source: Critical Reviews in Oncology Hematology - June 9, 2009 Category: Cancer & Oncology Authors: G. Okunade, A.R. Green, M. Ying, A. Agrawal, E.C. Paish, M. Aleskandrany, L. Winterbottom, K. Hassell, D.A.L. Morgan, I.O. Ellis, K.L. Cheung Tags: Geriatric Oncology (under the auspices of SIOG) Source Type: journals

Effects of morphine on testosterone levels in rat C6 glioma cells: Modulation by anastrozoleEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Rat C6 glioma cells are commonly used to investigate the functions of glial cells. To evaluate the presence of testosterone and its metabolism in rat C6 glioma cells, we cultured them in media with or without the addition of testosterone propionate and anastrozole, a blocker of aromatase, the enzyme needed to transform testosterone into estradiol. The same procedure was repeated with morphine (10 and 100 µM), known to decrease testosterone levels in the brain (in rats) and plasma (in rats and humans). Confluent cells were exposed to the test media for 48 h and then collected. Cell pellets were used to determine testostero...
Source: Journal of Cellular Physiology - June 2, 2009 Category: Cytology Authors: Ilaria Ceccarelli, Antonella Rossi, Melinda Maddalena, Elisabetta Weber, Anna Maria Aloisi Source Type: journals

Expression of the K303R Estrogen Receptor-{alpha} Breast Cancer Mutation Induces Resistance to an Aromatase Inhibitor via Addiction to the PI3K/Akt Kinase PathwayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Aromatase inhibitors (AI) are rapidly becoming the first choice for hormonal treatment of estrogen receptor- (ER)–positive breast cancer in postmenopausal women. However, de novo and acquired resistance frequently occurs. We have previously identified a lysine to arginine transition at residue 303 (K303R) in ER in premalignant breast lesions and invasive breast cancers, which confers estrogen hypersensitivity and resistance to tamoxifen treatment. Thus, we questioned whether resistance to AIs could arise in breast cancer cells expressing the ER mutation. As preclinical models to directly test this possibility, we gen...
Source: Cancer Research - June 1, 2009 Category: Cancer & Oncology Authors: Barone, I., Cui, Y., Herynk, M. H., Corona-Rodriguez, A., Giordano, C., Selever, J., Beyer, A., Ando, S., Fuqua, S. A.W. Tags: Endocrinology Source Type: journals

Ruptured gallbladder as the first presentation of breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: We present a rare case of gall bladder perforation from metastatic breast cancer. (Source: World Journal of Surgical Oncology)
Source: World Journal of Surgical Oncology - June 1, 2009 Category: Cancer & Oncology Authors: M JonesJ MathewKe AbdullahT McCullochKl Cheung Source Type: journals

History of aromatase: saga of an important biological mediator and therapeutic target.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Aromatase is the enzyme that catalyzes the conversion of androgens to estrogens. Initial studies of its enzymatic activity and function took place in an environment focused on estrogen as a component of the birth control pill. At an early stage, investigators recognized that inhibition of this enzyme could have major practical applications for treatment of hormone-dependent breast cancer, alterations of ovarian and endometrial function, and treatment of benign disorders such as gynecomastia. Two general approaches ultimately led to the development of potent and selective aromatase inhibitors. One targeted the enzyme us...
Source: ENDOCR REV - May 31, 2009 Category: Endocrinology Authors: Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A Tags: Endocr Rev Source Type: journals

Enhancing the efficacy of hormonal agents with selected targeted agents.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Several selected targeted agents are being investigated in combination with endocrine therapy for patients with breast cancer in an attempt to overcome or prevent endocrine resistance. The role of type I growth factor receptors epidermal growth factor receptor (EGFR) and HER2 in cross-talk with estrogen receptor (ER) signaling has been confirmed in preclinical studies in which various inhibitors have yielded additive or synergistic effects when combined with endocrine agents. Recently, several results from clinical trials investigating this concept have been reported. In ER-positive/HER-positive advanced breast cancer,...
Source: Clinical Breast Cancer - May 31, 2009 Category: Cancer & Oncology Authors: Johnston SR Tags: Clin Breast Cancer Source Type: journals

Arimidex (Anastrozole) - updated on RxListEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Arimidex (Anastrozole) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 29, 2009 Category: Drugs & Pharmacology Source Type: consumer

Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Expert Opinion on Pharmacotherapy , Early Online, Vol. 0, No. 0. (Source: Expert Opinion: Expert Opinion on Pharmacotherapy: Table of Contents)
Source: Expert Opinion: Expert Opinion on Pharmacotherapy: Table of Contents - May 15, 2009 Category: Drugs & Pharmacology Tags: article Source Type: journals

A Case of Brain Metastases from Breast Cancer that Responded to Anastrozole MonotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: The Breast Journal)
Source: The Breast Journal - May 15, 2009 Category: Cancer & Oncology Authors: Ken-ichi Ito, Tokiko Ito, Toshihiro Okada, Takayuki Watanabe, Kuniyuki Gomi, Toshiharu Kanai, Yasuhiro Mochizuki, Jun Amano Source Type: journals

21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study examined postmenopausal estrogen receptor-positive breast cancer patients who received prospective neoadjuvant endocrine therapy (NAET) with tamoxifen or anastrozole to determine if the 21-gene recurrence score (RS) predicts NAET responses. RS scores were determined from pretreatment core biopsy specimens. Although half of the specimens yielded insufficient RNA, the remaining samples were highly representative. Patients with a low RS tended to respond better than those with an intermediate or high RS (n=43). Response rates by RS were similar between the tamoxifen and anastrozole groups. Patients with a low RS te...
Source: The Breast - May 4, 2009 Category: Cancer & Oncology Authors: Sadako Akashi-Tanaka, Chikako Shimizu, Masashi Ando, Tatsuhiro Shibata, Noriyuki Katsumata, Tsutomu Kouno, Kotoe Terada, Tadahiko Shien, Miwa Yoshida, Takashi Hojo, Takayuki Kinoshita, Yasuhiro Fujiwara, Kenichi Yoshimura Tags: Original Articles Source Type: journals

The effect of anastrozol on spatial memory in adult ratsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract  Androgens are known to affect cognitive functions via organizational and activational effects. It is unknown whether the effects are mediated via the androgen receptor or after conversion to estradiol with aromatase via estrogen receptors. The aim of our study was to find out whether testosterone affects spatial memory directly or through its metabolite estradiol. Rats were treated with testosterone; with testosterone and the aromatase blocker anastrozole or saline. An 8 radial arm maze was used for testing spatial memory twice daily for 4 days. Each arm was baited with food, and the ability of anim...
Source: Central European Journal of Biology - May 3, 2009 Category: Biology Tags: Central European Journal of Biology Source Type: journals

21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study examined postmenopausal estrogen receptor-positive breast cancer patients who received prospective neoadjuvant endocrine therapy (NAET) with tamoxifen or anastrozole to determine if the 21-gene recurrence score (RS) predicts NAET responses. RS scores were determined from pretreatment core biopsy specimens. Although half of the specimens yielded insufficient RNA, the remaining samples were highly representative. Patients with a low RS tended to respond better than those with an intermediate or high RS (n=43). Response rates by RS were similar between the tamoxifen and anastrozole groups. Patients with a low RS te...
Source: Breast - April 29, 2009 Category: Cancer & Oncology Authors: Akashi-Tanaka S, Shimizu C, Ando M, Shibata T, Katsumata N, Kouno T, Terada K, Shien T, Yoshida M, Hojo T, Kinoshita T, Fujiwara Y, Yoshimura K Tags: Breast Source Type: journals

Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas—A pilot studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Prolonged combined anastrozole and goserelin down-regulation significantly reduces endometriomal volume and serum CA125, and is compatible with IVF pregnancy and delivery. However, a high pregnancy loss was noted. (Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology)
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - April 21, 2009 Category: OBGYN Authors: Kristine Lossl, Anne Loft, Nina L.C. Freiesleben, Susanne Bangsbøll, Claus Yding Andersen, Anette T. Pedersen, Dorthe Hartwell, Anders Nyboe Andersen Tags: Reproductive Medicine and Endrocrinology Source Type: journals

Adherence to Adjuvant Endocrine Therapy in Postmenopausal Women With Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Adherence to adjuvant endocrine treatment with tamoxifen or anastrozole in a randomly selected sample of postmenopausal women with primary breast cancer is evaluated in this study. Annals of Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 17, 2009 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: info

Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Clinical trials have shown that aromatase inhibitors (AIs) are an important advance in the treatment of early stage breast cancer (ESBC), but practice patterns and the impact of treatment side effects of endocrine therapy in the community setting have not been extensively explored. This retrospective chart review describes practice patterns among patients receiving adjuvant endocrine therapy for ESBC. Charts of 200 patients with confirmed stage I-IIIA breast cancer were reviewed. Patients received first-line treatment with tamoxifen (n=96) or AIs (n=104). Fifty-one patients completed a structured interview regarding sy...
Source: Breast - March 31, 2009 Category: Cancer & Oncology Authors: Schwartzberg LS, Cobb P, Senecal F, Henry D, Kulig K, Walker MS, Houts AC, Stepanski EJ Tags: Breast Source Type: journals

Improved survival in patients with breast rhabdoid tumors with multi-agent adjuvant chemotherapy combined with irradiationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion  Multi-agent chemotherapy combined with irradiation may be associated with the relatively long survival of the present case. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-009-0989-6Authors Yoshitaka Furuya, Sodegaura Satsukidai Hospital Department of Surgery 5-21 Nagauraekimae Sodegaura Chiba 299-0246 JapanHironobu Yanagie, The University of Tokyo Hospital, The University of Tokyo Cooperative Unit of Medicine and Engineering Research Tokyo JapanTakashi Wakahara, Sodegaura Satsukidai Hospital Department of Surgery 5-21 Nagauraekimae Sodegaura Chiba 299-0246 JapanYos...
Source: Cancer Chemotherapy and Pharmacology - March 26, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Immunologic Role of Anastrozole as a Potent Accelerator of Experimental Postmenopausal Polyarthritis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Aromatase inhibitors have become the standard of care for the adjuvant treatment of postmenopausal, hormone-sensitive breast cancer. Meanwhile, more and more breast cancer patients who are treated with aromatase inhibitors as adjuvant therapies often experience arthralgias and musculoskeletal aching, in some cases, have necessitated discontinuation of treatment. We therefore use a rat model of human RA to test the hypothesis that anastrozole, an aromatase inhibitor, could enhance arthritis. The parameters used for analyzing the disease severity included paw volume, radiology, histopathological examination, markers for ...
Source: Experimental Gerontology - March 16, 2009 Category: Geriatrics Authors: Jingxuan W, Qingyuan Z, Shi J, Meiyan F, Xinmei K, Shu Z, Shuling L, Zhao W Tags: Exp Gerontol Source Type: journals

ARIMIDEX Offers Women Greater Protection Against HR+ Early Breast Cancer Returning In The 1st 2 YrsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"Anastrozole is the only aromatase inhibitor (AI) which has now been shown to prevent recurrences in women with hormone receptor positive early breast cancer both during the initial high-risk two years after surgery, and also well beyond the completion of treatment. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 13, 2009 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Arimidex offers women greater protection against HR+ early breast cancer returning in the 1st 2 yrsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
“Anastrozole is the only aromatase inhibitor (AI) which has now been shown to prevent recurrences in women with hormone receptor positive early breast cancer both during the initial high-risk two years after surgery, and also well beyond the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2009 Category: Pharmaceuticals Source Type: news

FDA Safety Changes: Arimidex, Coreg/Coreg CR, MyozymeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FDA has approved revisions to the safety labeling for anastrozole tablets (Arimidex), carvedilol tablets and extended-release tablets (Coreg, Coreg CR), and alglucosidase alfa injection (Myozyme). Medscape Medical News (Source: Medscape PublicHealth Headlines)
Source: Medscape PublicHealth Headlines - March 11, 2009 Category: Primary Care Tags: Pharmacist Source Type: info

Aromatase InhibitorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Arimidex, Aromasin, and Femara are three aromatase inhibitors given as follow-up treatment after primary treatment for estrogen-receptor positive breast cancer. Aromatase inhibitors prevent the production of estrogen by inhibiting the enzyme aromatase. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 7, 2009 Category: Cancer & Oncology Tags: health Source Type: consumer

Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Adjuvant endocrine therapy remains the principle strategy to reduce recurrence risk in postmenopausal women with early breast cancer. Studies of the natural history of breast cancer have shown that, while not reaching zero at any time point, the risk of recurrence is highest in the first 5 years following initial diagnosis and treatment. Within this initial 5 years, there is a peak of recurrence at the 2- to 3-year mark. Among the types of breast cancer recurrences observed at this early peak, distant metastasis (DM) predominates over local or contralateral relapse. DM recurrences are most strongly linked to breast-can...
Source: Breast Cancer - March 4, 2009 Category: Cancer & Oncology Authors: Toi M, Yamashiro H, Tsuji W Tags: Breast Cancer Source Type: journals

Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Prolonged combined anastrozole and goserelin down-regulation significantly reduces endometriomal volume and serum CA125, and is compatible with IVF pregnancy and delivery. However, a high pregnancy loss was noted. PMID: 19261371 [PubMed - as supplied by publisher] (Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology)
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - March 2, 2009 Category: OBGYN Authors: Lossl K, Loft A, Freiesleben NL, Bangsbøll S, Andersen CY, Pedersen AT, Hartwell D, Andersen AN Tags: Eur J Obstet Gynecol Reprod Biol Source Type: journals

Women With Oestrogen Receptor Positive Early Breast Cancer Should Receive Aromatase Inhibitors Upfront - New NICE Clinical GuidelinesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
AstraZeneca welcomes the National Institute for Health and Clinical Excellence (NICE) Early Breast Cancer (EBC) clinical guideline (1) that recommends upfront use of aromatase inhibitors (AIs), such as anastrozole (Arimidex),Anastrozole (Arimdex)(2) in women who are not deemed to be low risk, which will help to ensure that postmenopausal women with oestrogen (ER) positive EBC receive the most appropriate treatment available. (Source: Cardiovascular / Cardiology News From Medical News Today)
Source: Cardiovascular / Cardiology News From Medical News Today - February 27, 2009 Category: Cardiology Tags: Heart Disease Source Type: news